Peripheral vascular disease is becoming a mainstream treatment area for the medical device industry. Rising rates of peripheral arterial disease (PAD), a shift from open surgery to catheter-based care, and a steady stream of new products are pushing the market toward a new scale. This post covers the numbers, the companies competing for share, and the buyers whose decisions shape demand.

Key Market Metrics

According to Grand View Research, the global peripheral vascular devices market was valued at USD 9.5 billion in 2025. It is estimated at USD 10.2 billion in 2026 and projected to reach USD 16.1 billion by 2033, a CAGR of 6.6% over 2026-2033.

• Largest region (2025): North America, with a 47.1% revenue share
• Fastest-growing region: Asia Pacific
• Leading type (2025): Peripheral stents, with a 22.2% share
• Leading application (2025): PAD, with a 46.6% share
• Leading end use (2025): Hospitals, with a 40.5% share

What is driving growth

• Disease burden. A study cited in the report projects global PAD prevalence to rise by roughly 220% by 2050, to around 360 million cases. More than half of those are expected in low- and middle-income countries. Diabetes and other metabolic disorders are a major contributor.
• Minimally invasive care. Clinicians increasingly favor angioplasty, stenting, and atherectomy over open surgery because of lower procedural risk, shorter stays, and faster recovery.
• Clinical evidence. Ongoing trials, such as BD's AGILITY study of its vascular covered stent in PAD across 40 sites, validate current technologies and open the way for new ones.
• Technology. Drug-eluting capabilities, bioresorbable materials, drug-coated balloons, and intravascular lithotripsy are widening the set of treatable lesions.

Where the fastest growth sits

• Aneurysms is the fastest-growing application. Incidence rises with age and with smoking, and abdominal aortic aneurysms are 4-6 times more common in males, particularly those over 60.
• Peripheral accessories, including closure devices, guidewires, and sheaths, is the fastest-growing type. Every additional endovascular procedure pulls these supporting devices along with it.
• Asia Pacific has the highest regional CAGR, backed by expanding healthcare infrastructure and a growing vascular disease burden.

The report characterizes the market as having a medium degree of innovation, moderate M&A activity, moderate regulatory impact, and low threat from substitutes. Exercise therapy, drugs, and bypass surgery exist as alternatives, but none directly replaces endovascular intervention.

Go Deeper! Ask Prism AI: Ask Prism AI about the Global Peripheral Vascular Devices Market. Get instant answers to questions related to market sizing, growth drivers and their impact, and more.

Prominent Industry Competitors

The report profiles twelve companies: Abbott, Koninklijke Philips N.V., Edwards Lifesciences Corporation, Medtronic, Teleflex Incorporated, Boston Scientific Corporation, BD, Terumo Corporation, W. L. Gore & Associates, Cordis, Cook Group, and B. Braun SE. Competition centers on new product launches, portfolio-building acquisitions, and regional expansion.

Recent moves that show where the field is heading

• Boston Scientific announced an agreement in January 2026 to acquire Penumbra, adding thrombectomy and clot-removal technology. This follows its September 2024 acquisition of Silk Road Medical, and the company also launched the Sterling SL peripheral PTA balloon catheter in the U.S. in April 2025.
• Abbott received CE Mark in August 2025 for the Esprit BTK resorbable scaffold, a dissolvable, drug-delivering stent for below-the-knee PAD. In March 2026 it also introduced its XIENCE Skypoint drug-eluting stent in India.
• Johnson & Johnson launched the Shockwave Javelin Peripheral IVL Catheter in Europe in September 2025 to address calcified, severely narrowed vessels.
• BD reached a milestone in the AGILITY study in November 2025 for its Revello vascular covered stent.
• W. L. Gore won FDA approval in January 2025 for the VIABAHN FORTEGRA Venous Stent, the first stent specifically indicated for deep venous disease in the IVC and iliofemoral veins.
• Medtronic received expanded CE Mark indications in May 2025 for its Prevail drug-coated balloon, including complex bifurcation lesions.
• Cook Medical gained FDA approval in May 2025 for an updated Zenith Iliac Branch device for aortoiliac aneurysms.
• Regional consolidation is also visible. Zylox-Tonbridge agreed to acquire Optimed in Germany in January 2026, and Kaneka's earlier acquisition of Japan Medical Device Technology strengthened its stent expertise in Japan.

Three patterns stand out. Large players are buying their way into high-growth niches such as thrombectomy and IVL. Resorbable and drug-delivering technologies are moving from novelty to mainstream. And companies are using regulatory approvals in Europe, the U.S., and emerging markets to stagger their launches.

Take the Next Step! Speak to an Analyst: Have questions about the peripheral vascular devices market or need guidance on how the findings apply to your strategy? Speak to an Analyst from our medical devices research team.

End Users & Purchasing Dynamics

Hospitals are the anchor buyers. They held the largest end-use share at 40.5% in 2025. Their specialized surgical units, advanced imaging, and trained interventional teams make them the default setting for complex procedures. Institutions are also building dedicated programs. In February 2025, University Hospitals Harrington Heart & Vascular Institute established a Limb Preservation Center for multidisciplinary PAD care aimed at preventing amputations. Programs like this tend to concentrate purchasing around a coordinated team rather than individual physicians.

Ambulatory surgical centers (ASCs) are the fastest-growing channel. Cost containment, patient preference for shorter stays, and the shift to minimally invasive therapy are moving appropriate procedures out of the hospital. A February 2026 article in Ambulatory Surgery Center News reported that select ASCs performing percutaneous coronary interventions had complication rates of about 1%, comparable to hospitals, with savings of roughly USD 4,000 per procedure. For manufacturers, ASCs favor products that support efficient patient flow, such as low-profile devices and advanced closure systems that shorten time to hemostasis and ambulation.

Practical implications for suppliers

• Clinical evidence supports adoption. Trial data and regulatory approvals carry weight, especially for high-risk devices such as drug-eluting products, where regulators have tightened requirements.
• Portfolio breadth matters. Treating a patient typically involves stents, balloons, catheters, guidewires, sheaths, and closure devices. This favors companies that can cover more of the procedure.
• Site-of-care shifts change the pitch. The ASC channel puts more weight on procedural efficiency and cost per case alongside clinical performance.
• Geography shapes the playbook. North America leads in revenue, while Asia Pacific, Latin America, and the Middle East and Africa offer growth where PAD risk factors like diabetes and obesity are rising and healthcare infrastructure is expanding.

Know Your Buyers: Understand the hospitals behind these purchasing decisions. Explore the U.S. Healthcare Facility Mapping & Intelligence Platform to identify and profile target institutions.